Determining the effectiveness of celecoxib in reducing the severity of SAP

Determining the effectiveness of the drug celecoxib (cyclooxygenase 2 inhibitor) in reducing the severity of SAP (severe acute pancreatitis)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250412065298N1

Enrollment

200

Registered

2025-05-03

Start date

2025-05-04

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis. Acute pancreatitis

Interventions

Intervention 1: Intervention group: This study evaluates the efficacy of adjunctive COX-2 inhibitor therapy to standard treatment regimens in acute pancreatitis management, specifically investigating

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Any patient diagnosed as AP in the emergency department will be re-evaluated according to the Atlanta criteria defined in 2012 to make a definitive diagnosis of AP. The mean age of patients at study entry is 18 to 75 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CRP. Timepoint: Standardized as T+48h, D3, D5 in research protocols. Method of measurement: On the mentioned days (48h post-medication, Day 3, and Day 5), blood samples are collected from patients to measure and analyze serum levels of the inflammatory biomarkers IL-6 (Interleukin-6) and CRP (C-reactive Protein.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Hasannezhad

Ahvaz University of Medical Sciences

maryamhasannezhad@yahoo.com+98 61 3332 5431

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026